At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (SCCHN) with recurrent, persistent, or newly diagnosed metastatic disease
- ✓Measurable or non-measurable disease
- ✓Age 18 years or older
- ✓Zubrod performance status 0-1
- ✕Active or prior CNS metastasis
- ✕Symptomatic sensory neuropathy grade 2 or higher
- ✕History of hypersensitivity reaction to products containing polysorbate 80
- ✕Active infection requiring systemic antibiotic therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Biweekly Gemcitabine and Paclitaxel (GEMTAX) Combination in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
In Brief
A Phase 2 clinical trial evaluating gemcitabine and paclitaxel for Head and Neck Cancer. Completed, enrolled 67 participants across 123 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine together with paclitaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with paclitaxel works in treating patients with persistent, recurrent, or metastatic head and neck cancer.
Study Details
Timeline
Interventions
3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).
150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine